Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 246 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammation of Mouth Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparison of Gingival Flap Procedure Using Conventional Surgical Loupes vs. Videoscope for Visualization

NCT05932017
View directory record Official record
Conditions
Periodontal Diseases, Periodontal Pocket, Periodontitis, Periodontal Inflammation, Periodontal Attachment Loss, Periodontal Bone Loss, Surgery
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 2, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

NCT01403064
View directory record Official record
Conditions
Oral Mucositis
Interventions
ALD518, 0.9% saline
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Turmeric and Turmeric-containing Tablets and Sebum Production

NCT03065504
View directory record Official record
Conditions
Skin Inflammation
Interventions
Turmeric, Turmeric-containing combination tablet, Placebo tablets
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

NCT06974604
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms
Interventions
Dexamethasone oral
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858
View directory record Official record
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Effectiveness of Toothpaste Tablets on Plaque, Gingival Health and Caries Experiences

NCT07124533
View directory record Official record
Conditions
Gingival Inflammation, Dental Caries
Interventions
Toothpaste Tablet, Conventional Toothpaste
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Phase 4 Interventional

Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients

NCT06819033
View directory record Official record
Conditions
Aphthous Ulcer
Interventions
PBM Therapy, Maalox plus Benadryl
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 2, 2026, 11:23 AM EDT
Terminated No phase listed Observational

An Exploratory Study on Optical Assessment of Oral Mucositis

NCT00488332
View directory record Official record
Conditions
Head and Neck Cancer, Oral Mucositis
Interventions
Optical Coherence Tomography, Fluorescence Spectroscopy, Pain Scale Questionnaire
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

NCT00323518
View directory record Official record
Conditions
Oral Mucositis, Stomatitis
Interventions
velafermin, placebo
Drug
Lead sponsor
CuraGen Corporation
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Little Rock, Arkansas • Berkley, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 2, 2026, 11:23 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Induction of Gut Permeability by an Oral Vaccine

NCT04083950
View directory record Official record
Conditions
Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
Interventions
Vivotif Typhoid Oral Vaccine, Aspirin (Positive Control)
Biological · Drug
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 2, 2026, 11:23 AM EDT
Withdrawn No phase listed Observational

Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant

NCT02589860
View directory record Official record
Conditions
Mucositis, Multiple Myeloma, Amyloidosis, Oral Mucositis
Interventions
Melphalan kinetic study, Oral bacterial study, Gene expression study
Other · Genetic
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 2, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

NCT00075023
View directory record Official record
Conditions
Graft-versus-Host Disease, Stomatitis
Interventions
Thalidomide Gel, Placebo Gel
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year

NCT00000848
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
16
States / cities
Palo Alto, California • San Francisco, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of RK0202 in Oral Mucositis

NCT00230191
View directory record Official record
Conditions
Mouth Diseases, Mouth Ulcers, Oral Mucositis, Head and Neck Cancer
Interventions
RK-0202
Drug
Lead sponsor
RxKinetix
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2007 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Characterize the Effect of Heparin on Palifermin Activity

NCT01163097
View directory record Official record
Conditions
Oral Mucositis
Interventions
Palifermin, Heparin
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck

NCT00938080
View directory record Official record
Conditions
Oral Mucositis
Interventions
AG013, Placebo
Biological · Other
Lead sponsor
ActoGeniX N.V.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 2, 2026, 11:23 AM EDT
Not yet recruiting Phase 2 Interventional

Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse

NCT06660017
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Placebo, Ketamine Topical
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 2, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

NCT03850509
View directory record Official record
Conditions
Crohn's Disease
Interventions
OPS-2071, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
24
States / cities
Los Angeles, California • San Carlos, California • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 3 Interventional

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 2, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions

NCT04893577
View directory record Official record
Conditions
Herpes Simplex Oral
Interventions
EDTA, Abreva
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 2, 2026, 11:23 AM EDT
Recruiting Not applicable Interventional

F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)

NCT06315855
View directory record Official record
Conditions
Oral Mucositis, Periodontal Diseases, Cancer
Interventions
Telehealth Intervention (THI)
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 2, 2026, 11:23 AM EDT